Strides Shasun and Sequent to merge API units as standalone firm

By Gareth Macdonald

- Last updated on GMT

iStock/eyegelb
iStock/eyegelb

Related tags Fiscal year

Strides Shasun Ltd and Sequent Scientific Ltd have announced they will combine their API units into a standalone company.

The new firm – which has not been named – will have a network of five manufacturing facilities, including the US Food and Drug Administration (FDA) approved plant Strides Shasun is buying from Perrigo​.

Strides announced its intention to hive off its ingredient business in August​, explaining that a separate leadership team would be better able to ensure the firm complies with regulations covering active pharmaceutical ingredient (API) production.

SeQuent – which is majority-owned by Shasun promoter Arun Kumar – said merging its API business with Strides’ would allow it to become a “pure play” animal health company​.

It added that its API business – which is focused on mature small volume molecules - is “sub-scale.”

Sequent added that it “decided to divest the human API business, which though profitable, will require significant CapEx to build scale and capabilities.”

The firms predicted the spin out would be completed in October, subject to shareholder approval.

API business

APIs generated INR7.12bn ($105.6m) for Strides in the fiscal year 2016, roughly flat compared with the year earlier period.

At the time Strides said: “API delivered a steady performance in FY 16 despite impact of incessant rains in the state of Tamil Nadu​.”

Sequent has human API production facilities in Mangalore, Mahad and Mysore in India.

According to a Bombay Stock Exchange (BSE) filing, Sequent’s API business brings in INR3bn a year, equivalent to 27% of the company’s annual sales.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines